CVAid Medical
AI-based Stroke Disease Management Platform
Company Overview
Snapshot
Founded in October 2018 by Danny Farin, Oren Dror, Rotem Sivan-Hoffmann, and Nadav Eichler, CVAid Medical operates with 1–10 employees. The company has raised $4 million across two funding rounds from four investors. In February 2022, CVAid Medical secured funding from RAD BioMed, Phillips Ventures, and Sanara Capital.
Business overview
CVAid Medical develops an AI-based stroke disease management platform, CVA-Flow, designed to improve stroke diagnosis and patient outcomes. The company's core technology leverages a proprietary database of visual and auditory stroke patient recordings, along with machine and deep learning tools, to provide real-time data analysis and decision support for neurologists. CVAid Medical serves the healthcare industry, offering a full-cycle platform that encompasses pre-hospital early diagnosis, in-hospital process management, and post-discharge follow-up, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare, Digital Medical Diagnostics, and Medical Decision Support.
Strategic signal
In February 2022, CVAid Medical secured funding from RAD BioMed, Phillips Ventures, and Sanara Capital. This investment signals continued investor confidence in the company's AI-driven telestroke solution and its potential to significantly impact stroke diagnosis and management. For investors, this indicates strategic validation of CVAid Medical's technology and market approach in the rapidly evolving digital health landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is CVAid Medical's primary focus?
- CVAid Medical focuses on stroke telemedicine, aiming to improve stroke diagnosis and management through its AI-based platform, CVA-Flow.
- When was CVAid Medical founded?
- CVAid Medical was founded in October 2018.
- Who are the founders of CVAid Medical?
- The co-founders of CVAid Medical are Danny Farin, Oren Dror, Rotem Sivan-Hoffmann, and Nadav Eichler.
- What is CVAid Medical's core product?
- CVAid Medical's core product is CVA-Flow, a comprehensive telestroke system supported by its artificial-intelligence module, CVA-Core, designed for early and accurate stroke diagnosis and disease management.
- Which investors participated in CVAid Medical's February 2022 funding round?
- In February 2022, CVAid Medical received funding from RAD BioMed, Phillips Ventures, and Sanara Capital.